Should we question our current model for encouraging innovation in the pharmaceutical sector?

The Sciences Po Health Chair, Sciences Po Law School and the Law and Health Institute of Paris University invite you to a panel discussion on the question ">Is access to medicines a right?". These conferences will take the form of a series of questions to which speakers from various fields of expertise and countries will be invited to provide elements of response. Through concrete examples, fueled in particular by the COVID-19 pandemic, academics, civil servants, civil society actors, industrial actors and public decision-makers will be invited to present their thoughts and to dialogue with students from Sciences Po and the Law and Health Institute as well as with a wider audience around the major issue of access to medicines.

The four questions raised by this series of panel discussions will be:

• "Is access to medicines a right?" (February 2022, in English)
• "Should we question our current model for encouraging innovation in the pharmaceutical sector?" (March 2022, in English)
• "How can we ensure our health independence in terms of access to medicines?" (April 2022, in French)
• "What would be the impact of a greater transparency of certain activities of the pharmaceutical industry on access to medicines?" (May 2022, in French)

With the participation of:

• Marie-Paule Kieny, Director of Research at Inserm, Chair of the Board of Drugs for Neglected Diseases Initiative (DNDi), Chair of the Governance Board of Medicines Patent Pool Foundation (MPPF)

• Margaret Kyle, Professor of Economics at MINES ParisTech

• Suerie Moon, Co-director of the Global Health Center, Professor of practice, interdisciplinary programmes and international relations/political sciences at the Graduate Institute Geneva

• Thomas Pogge, Leitner Professor of Philosophy and International Affairs at Yale University, co-founder of the Health Impact Fund initiative

• Jean-Hugues Trouvin, Professor (Hon) University of Paris, school of Pharmacy, former Chairman of the Biologics working Party (BWP), European Medicines Agency